S&CO Inc. bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 81,497 shares of the medical research company’s stock, valued at approximately $7,372,000.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $26,000. Hanson & Doremus Investment Management acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $25,000. Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $27,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $25,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $28,000. Institutional investors and hedge funds own 79.46% of the company’s stock.
Insider Transactions at Edwards Lifesciences
In other news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 26,190 shares of company stock worth $2,269,697 over the last quarter. 0.31% of the stock is currently owned by insiders.
Edwards Lifesciences Stock Down 1.1%
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.
Analysts Set New Price Targets
EW has been the topic of a number of analyst reports. Barclays reiterated an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Robert W. Baird boosted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $100.27.
Read Our Latest Stock Analysis on Edwards Lifesciences
About Edwards Lifesciences
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Read More
- Five stocks we like better than Edwards Lifesciences
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
